Articles related to DRUG SAFETY & INTERACTIONS

A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.

The American Academy of Ophthalmology updated hydroxychloroquine retinopathy screening recommendations, emphasizing dose limits, OCT and FAF as primary screening modalities, and risk stratification by renal status and concurrent tamoxifen use.

The FDA approved dextromethorphan-bupropion (Auvelity) for agitation associated with dementia due to Alzheimer’s disease, based on phase 3 trial data and a long-term randomized withdrawal study.

VMAT2 inhibitors were associated with lower rates of falls, injuries, fractures, and several secondary adverse outcomes than anticholinergic agents in a propensity-matched cohort of adults with tardive dyskinesia.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Eleven commonly prescribed medication classes have been associated with new or worsening depression symptoms, with risk varying by dose, duration, and patient population.